[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Merck & Company (MRK)

Merck & Company (MRK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 285,116,480
  • Shares Outstanding, K 2,469,824
  • Annual Sales, $ 65,011 M
  • Annual Income, $ 18,254 M
  • EBIT $ 12,969 M
  • EBITDA $ 18,807 M
  • 60-Month Beta 0.21
  • Price/Sales 4.38
  • Price/Cash Flow 10.08
  • Price/Book 6.19

Options Overview Details

View History
  • Implied Volatility 28.60% (+1.08%)
  • Historical Volatility 29.93%
  • IV Percentile 45%
  • IV Rank 48.07%
  • IV High 36.10% on 07/08/25
  • IV Low 21.66% on 12/08/25
  • Expected Move (DTE 7) 3.30 (2.90%)
  • Put/Call Vol Ratio 0.47
  • Today's Volume 23,178
  • Volume Avg (30-Day) 28,301
  • Put/Call OI Ratio 0.98
  • Today's Open Interest 514,772
  • Open Int (30-Day) 517,515
  • Expected Range 110.57 to 117.17

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 29 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $2.10
  • Number of Estimates 3
  • High Estimate $2.18
  • Low Estimate $2.02
  • Prior Year $2.13
  • Growth Rate Est. (year over year) -1.41%

Price Performance

See More
Period Period Low Period High Performance
1-Month
111.57 +2.06%
on 06/18/26
123.46 -7.77%
on 06/05/26
+1.31 (+1.16%)
since 05/18/26
3-Month
107.90 +5.53%
on 04/29/26
124.00 -8.17%
on 04/09/26
-0.63 (-0.55%)
since 03/18/26
52-Week
76.66 +48.54%
on 07/29/25
125.14 -9.01%
on 02/25/26
+34.58 (+43.61%)
since 06/18/25

Most Recent Stories

More News
U.S. FDA Approves an Additional Indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in Children and Adolescents Aged 2 through 17 at Increased Risk for Pneumococcal Disease

CAPVAXIVE is the only Pneumococcal Conjugate Vaccine (PCV) specifically indicated and studied in the U.S. for use in this population CAPVAXIVE, when added to existing...

MRK : 113.87 (-1.36%)
Study Reveals Dog Owners and Veterinarians See Challenges in Treating Allergic Skin Disease, Highlighting a Need for a Targeted Rapid Onset Treatment for Dogs of All Ages

Efficacy and safety are top preferences when selecting antipruritic treatments, but dog owners and veterinarians want options that are easier to administer, more affordable and improve compliance

MRK : 113.87 (-1.36%)
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With WELIREG® (belzutifan), for Adjuvant Treatment of Certain Patients With Clear Cell Renal Cell Carcinoma (ccRCC)

Marks the first approved combinations of a PD-1 and HIF-2α inhibitor Approvals based on Phase 3 LITESPARK-022 trial that showed KEYTRUDA in combination with WELIREG reduced...

MRK : 113.87 (-1.36%)
Merck Animal Health to Acquire TARGAN

TARGAN’s innovative high-speed biodevice technology, including its gender identification product WingScan™, delivers enhanced poultry performance

MRK : 113.87 (-1.36%)
Stocks Climb on an AI-Led Rebound

The S&P 500 Index ($SPX ) (SPY ) today is up +0.93%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.89%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.17%. June E-mini S&P futures (ESM26...

ALK : 49.26 (+2.05%)
MPC : 242.91 (-0.69%)
SNDK : 2,184.75 (+11.54%)
MTN : 144.78 (+11.43%)
OXY : 51.82 (-2.30%)
FANG : 183.50 (-1.07%)
STX : 1,070.23 (+0.39%)
WDC : 746.23 (+4.79%)
NUVL : 123.43 (+0.06%)
NOVT : 155.30 (+2.56%)
SPY : 746.74 (+1.04%)
MU : 1,133.99 (+8.70%)
Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment

– Novel Investigational Combination Pairs Merck’s Islatravir, a Next-Generation Nucleoside Analog with Distinct Mechanisms of Action, Including Reverse Transcriptase Translocation Inhibition, with...

MRK : 113.87 (-1.36%)
GILD : 123.76 (-1.35%)
Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Gilead Sciences, Inc. (Nasdaq: GILD) today announced the discontinuation of the Phase 3 KEYNOTE-D46/EVOKE-03 study investigating...

MRK : 113.87 (-1.36%)
GILD : 123.76 (-1.35%)
Apotex launches sitagliptin tablets and sitagliptin and metformin hydrochloride tablets, eligible for 180-day shared exclusivity

WESTON, Fla. , June 3, 2026 /PRNewswire/ - Apotex Corp. ("Apotex") today announced the U.S. launch of sitagliptin tablets and sitagliptin and metformin hydrochloride tablets, both of which are eligible...

MRK : 113.87 (-1.36%)
Merck to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Robert M. Davis, chairman and chief executive officer, and Dr. Dean Y. Li, executive vice president and president,...

MRK : 113.87 (-1.36%)
Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting

At a median 5-year (60.3 months) planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA demonstrated a 49% reduction in the risk of recurrence...

MRK : 113.87 (-1.36%)
MRNA : 63.96 (+3.50%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda,...

See More

Key Turning Points

3rd Resistance Point 118.72
2nd Resistance Point 116.83
1st Resistance Point 115.35
Last Price 113.87
1st Support Level 111.98
2nd Support Level 110.09
3rd Support Level 108.61

See More

52-Week High 125.14
Last Price 113.87
Fibonacci 61.8% 106.62
Fibonacci 50% 100.90
Fibonacci 38.2% 95.18
52-Week Low 76.66

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.